Table 2 DIPSS Score and Spleen Size in MF group at Baseline*.

From: Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms

DIPSS

N

%

BMI (kg/m2)

Spleen Size

N

%

BMI (kg/m2)

Low risk

10

20.0%

26.4 ± 4.8

Mild

18

36.7%

28.0 ± 4.8

Intermediate-1

24

48.0%

26.1 ± 5.0

Moderate

12

24.5%

24.6 ± 5.2

Intermediate-2

14

28.0%

25.5 ± 5.0

Severe

19

38.8%

25.2 ± 5.2

High risk

2

4.0%

22.9 ± 6.0

    
  1. *2 patients did not have data available for DIPSS score. 3 patients did not have data available for spleen size. BMI data are mean ± SD.
Back to article page